Literature DB >> 9755868

Phosphorylation of the translational regulator, PHAS-I, by protein kinase CK2.

P Fadden1, T A Haystead, J C Lawrence.   

Abstract

The primary site in PHAS-I for phosphorylation by protein kinase CK2 in vitro was identified as Ser111. A relatively small amount of phosphorylation of Ser99 was also detected, and mutating Ser99 to Ala in PHAS-I slightly decreased phosphorylation by CK2 in vitro. In contrast, mutating Ser111 to Ala almost abolished phosphorylation, confirming Ser111 as the preferred site for CK2. Phosphorylation of Ser111 did not decrease binding of PHAS-I to eIF4E, and results of peptide mapping experiments with PHAS-I immunoprecipitated from 32P-labeled adipocytes indicated that Ser111 was not phosphorylated in cells. These results support the conclusion that CK2 is not involved in the control of PHAS-I.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9755868     DOI: 10.1016/s0014-5793(98)01047-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  4 in total

1.  Regulation of protein synthesis by ionizing radiation.

Authors:  Steve Braunstein; Michelle L Badura; Qiaoran Xi; Silvia C Formenti; Robert J Schneider
Journal:  Mol Cell Biol       Date:  2009-08-24       Impact factor: 4.272

2.  Multiple mechanisms control phosphorylation of PHAS-I in five (S/T)P sites that govern translational repression.

Authors:  I Mothe-Satney; D Yang; P Fadden; T A Haystead; J C Lawrence
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

3.  Rapamycin-resistant mTORC1 kinase activity is required for herpesvirus replication.

Authors:  Nathaniel J Moorman; Thomas Shenk
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

4.  The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation.

Authors:  Xuemin Wang; Wei Li; Josep-Lluis Parra; Anne Beugnet; Christopher G Proud
Journal:  Mol Cell Biol       Date:  2003-03       Impact factor: 4.272

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.